Human Immunodeficiency Virus Hiv clinical trials

Explore recruiting human immunodeficiency virus hiv clinical trials.

Recruiting human immunodeficiency virus hiv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Human Immunodeficiency Virus Hiv trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed

Belgium, Italy, Portugal, Austria, Spain, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

IAVI C110 HIV Vaccine Trial

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A phase 1 Clinical Trial to Evaluate Safety and Immunogenecity of HIV SOSIP v8.2 763 Vaccine in healthy individuals

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3b, multi-center, randomized, parallel-group, open-label, non-inferiority study evaluating the efficacy, safety, and tolerability of oral dolutegravir/lamivudine once-daily as a first-line regimen compared to oral bictegravir/emtricitabine/tenofovir alafenamide once daily for virologic suppression and maintenance in antiretroviral therapy naive adults living with HIV

Spain, Greece, Ireland, Portugal, Germany, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Human Immunodeficiency Virus Hiv trials by city

Human Immunodeficiency Virus Hiv in Toronto Human Immunodeficiency Virus Hiv in Vancouver Human Immunodeficiency Virus Hiv in Montreal Human Immunodeficiency Virus Hiv in Calgary Human Immunodeficiency Virus Hiv in Edmonton Human Immunodeficiency Virus Hiv in Ottawa Human Immunodeficiency Virus Hiv in Winnipeg Human Immunodeficiency Virus Hiv in Quebec City Human Immunodeficiency Virus Hiv in Hamilton Human Immunodeficiency Virus Hiv in Kitchener Human Immunodeficiency Virus Hiv in London Human Immunodeficiency Virus Hiv in Halifax Human Immunodeficiency Virus Hiv in New York Human Immunodeficiency Virus Hiv in Los Angeles Human Immunodeficiency Virus Hiv in Chicago Human Immunodeficiency Virus Hiv in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease